Inactivation of Hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases

Molecular Therapy

Volumn 21, Issue 10, 2013, Pages 1889-1897

  Bloom, Kristie ^a   Ely, Abdullah ^a   Mussolino, Claudio ^b   Cathomen, Toni ^a   Arbuthnot, Patrick ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; COVALENTLY CLOSED CIRCULAR DNA; DNA; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE; UNCLASSIFIED DRUG; VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DNA SEQUENCE; DRUG EFFICACY; DRUG SAFETY; ENZYME ENGINEERING; GENE DISRUPTION; GENE MUTATION; GENE TARGETING; GENETIC TRANSFECTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HYDRODYNAMICS BASED TRANSFECTION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OPEN READING FRAME; POLYMERASE CHAIN REACTION; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS INACTIVATION; VIRUS REPLICATION;

HEPATITIS B VIRUS; MURINAE;

ANIMALS; BASE SEQUENCE; CELL LINE; DEOXYRIBONUCLEASES; DISEASE MODELS, ANIMAL; DNA REPLICATION; DNA, CIRCULAR; DNA, VIRAL; GENETIC THERAPY; GENETIC VECTORS; HEP G2 CELLS; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; MICE; MOLECULAR SEQUENCE DATA; MUTAGENESIS; PROTEIN ENGINEERING; TRANSFECTION; VIRUS REPLICATION;

EID: 84885023096     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.170     Document Type: Article

References (41)

1. El-Serag, HB (2012). Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142: 1264-1273.e1.
2. Perz, JF, Armstrong, GL, Farrington, LA, Hutin, YJ and Bell, BP (2006). The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45: 529-538.
3. Newbold, JE, Xin, H, Tencza, M, Sherman, G, Dean, J, Bowden, S et al. (1995). The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol 69: 3350-3357.
4. Tiollais, P, Pourcel, C and Dejean, A (1985). The hepatitis B virus. Nature 317: 489-495.
5. Levrero, M, Pollicino, T, Petersen, J, Belloni, L, Raimondo, G and Dandri, M (2009). Control of cccDNA function in hepatitis B virus infection. J Hepatol 51: 581-592.
6. Chen, HS, Kaneko, S, Girones, R, Anderson, RW, Hornbuckle, WE, Tennant, BC et al. (1993). The woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks. J Virol 67: 1218-1226.
7. Zoulim, F, Saputelli, J and Seeger, C (1994). Woodchuck hepatitis virus X protein is required for viral infection in vivo. J Virol 68: 2026-2030.
8. Arbuthnot, P, Capovilla, A and Kew, M (2000). Putative role of hepatitis B virus X protein in hepatocarcinogenesis: effects on apoptosis, DNA repair, mitogen-activated protein kinase and JAK/STAT pathways. J Gastroenterol Hepatol 15: 357-368.
9. Ayoub, WS and Keeffe, EB (2011). Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther 34: 1145-1158.
10. Cradick, TJ, Keck, K, Bradshaw, S, Jamieson, AC and McCaffrey, AP (2010). Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. Mol Ther 18: 947-954.
11. Zimmerman, KA, Fischer, KP, Joyce, MA and Tyrrell, DL (2008). Zinc finger proteins designed to specifically target duck hepatitis B virus covalently closed circular DNA inhibit viral transcription in tissue culture. J Virol 82: 8013-8021.
12. Joung, JK and Sander, JD (2013). TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol 14: 49-55.
13. Mussolino, C, Morbitzer, R, Lütge, F, Dannemann, N, Lahaye, T and Cathomen, T (2011). A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic Acids Res 39: 9283-9293.
14. Chudy, M, Hanschmann, KM, Kress, J, Nick, S, Campos, R, Wend, U et al. (2012). First WHO International Reference Panel containing hepatitis B virus genotypes A-G for assays of the viral DNA. J Clin Virol 55: 303-309.
15. Doyle, EL, Booher, NJ, Standage, DS, Voytas, DF, Brendel, VP, Vandyk, JK et al. (2012). TAL Effector-Nucleotide Targeter (TALE-NT) 2.0: tools for TAL effector design and target prediction. Nucleic Acids Res 40(Web Server issue): W117-W122.
16. Nassal, M (1992). The arginine-rich domain of the hepatitis B virus core protein is required for pregenome encapsidation and productive viral positive-strand DNA synthesis but not for virus assembly. J Virol 66: 4107-4116.
17. Sells, MA, Zelent, AZ, Shvartsman, M and Acs, G (1988). Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions. J Virol 62: 2836-2844.
18. Rabe, B, Glebe, D and Kann, M (2006). Lipid-mediated introduction of hepatitis B virus capsids into nonsusceptible cells allows highly efficient replication and facilitates the study of early infection events. J Virol 80: 5465-5473.
19. Laras, A, Koskinas, J, Dimou, E, Kostamena, A and Hadziyannis, SJ (2006). Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients. Hepatology 44: 694-702.
20. Doyon, Y, Choi, VM, Xia, DF, Vo, TD, Gregory, PD and Holmes, MC (2010). Transient cold shock enhances zinc-finger nuclease-mediated gene disruption. Nat Methods 7: 459-460.
21. Hwang, WY, Fu, Y, Reyon, D, Maeder, ML, Tsai, SQ, Sander, JD et al. (2013). Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol 31: 227-229.
22. Yang, PL, Althage, A, Chung, J and Chisari, FV (2002). Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci USA 99: 13825-13830.
23. Guidotti, LG, Matzke, B, Schaller, H and Chisari, FV (1995). High-level hepatitis B virus replication in transgenic mice. J Virol 69: 6158-6169.
24. Kim, Y, Kweon, J and Kim, JS (2013). TALENs and ZFNs are associated with different mutation signatures. Nat Methods 10: 185.
25. Schiffer, JT, Aubert, M, Weber, ND, Mintzer, E, Stone, D and Jerome, KR (2012). Targeted DNA mutagenesis for the cure of chronic viral infections. J Virol 86: 8920-8936.
26. Jurica, MS and Stoddard, BL (1999). Homing endonucleases: structure, function and evolution. Cell Mol Life Sci 55: 1304-1326.
27. Aiba, Y, Sumaoka, J and Komiyama, M (2011). Artificial DNA cutters for DNA manipulation and genome engineering. Chem Soc Rev 40: 5657-5668.
28. Hendrie, PC, Hirata, RK and Russell, DW (2003). Chromosomal integration and homologous gene targeting by replication-incompetent vectors based on the autonomous parvovirus minute virus of mice. J Virol 77: 13136-13145.
29. Kim, YG, Cha, J and Chandrasegaran, S (1996). Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc Natl Acad Sci USA 93: 1156-1160.
30. Cong, L, Ran, FA, Cox, D, Lin, S, Barretto, R, Habib, N et al. (2013). Multiplex genome engineering using CRISPR/Cas systems. Science 339: 819-823.
31. Fu, Y, Foden, JA, Khayter, C, Maeder, ML, Reyon, D, Joung, JK et al. (2013). Highfrequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol doi: 10.1038/nbt.2623 (in press).
32. Meuleman, P, Libbrecht, L, Wieland, S, De Vos, R, Habib, N, Kramvis, A et al. (2006). Immune suppression uncovers endogenous cytopathic effects of the hepatitis B virus. J Virol 80: 2797-2807.
33. Yang, W, Mason, WS and Summers, J (1996). Covalently closed circular viral DNA formed from two types of linear DNA in woodchuck hepatitis virus-infected liver. J Virol 70: 4567-4575.
34. Ding, D, Lou, X, Hua, D, Yu, W, Li, L, Wang, J et al. (2012). Recurrent targeted genes of hepatitis B virus in the liver cancer genomes identified by a next-generation sequencing-based approach. PLoS Genet 8: e1003065.
35. Morbitzer, R, Elsaesser, J, Hausner, J and Lahaye, T (2011). Assembly of custom TALEtype DNA binding domains by modular cloning. Nucleic Acids Res 39: 5790-5799.
36. Sells, MA, Chen, ML and Acs, G (1987). Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci USA 84: 1005-1009.
37. Chattopadhyay, S, Ely, A, Bloom, K, Weinberg, MS and Arbuthnot, P (2009). Inhibition of hepatitis B virus replication with linear DNA sequences expressing antiviral micro- RNA shuttles. Biochem Biophys Res Commun 389: 484-489.
38. Till, BJ, Burtner, C, Comai, L and Henikoff, S (2004). Mismatch cleavage by singlestrand specific nucleases. Nucleic Acids Res 32: 2632-2641.
39. Wong, DK, Yuen, MF, Yuan, H, Sum, SS, Hui, CK, Hall, J et al. (2004). Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. Hepatology 40: 727-737.
40. Abramoff, MD, Magelhaes, PJ and Ram, SJ (2004). Image Processing with ImageJ. Biophotonics Int 11: 36-42.
41. Tremblay, JP, Xiao, X, Aartsma-Rus, A, Barbas, C, Blau, HM, Bogdanove, AJ et al. (2013). Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases. Mol Ther 21: 266-268.